Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes |
Apr 2021 |
Hematology/oncology clinics of North America |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) |
Mar 2021 |
Cancers |
Chronic Myelomonocytic Leukaemia (CMML), Myelodysplastic Syndromes (MDS) |
Outcomes of pediatric patients who relapse after first HCT for acute leukemia or MDS |
Mar 2021 |
Bone Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia |
Mar 2021 |
Leukemia |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Germline mutations in MDS/AML predisposition disorders |
Mar 2021 |
Current opinion in hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management" |
Mar 2021 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes |
Feb 2021 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors |
Feb 2021 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM) |
Feb 2021 |
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantat |
Feb 2021 |
Journal for immunotherapy of cancer |
Myelodysplastic Syndromes (MDS) |